SS-31 / Elamipretide

Overview

SS-31, also known as Elamipretide (MTP-131, Bendavia), is a cell-permeable Szeto-Schiller tetrapeptide that concentrates selectively in the inner mitochondrial membrane through reversible association with cardiolipin. By stabilising cardiolipin-cytochrome-c interactions it is studied for its effect on electron-transport-chain efficiency and reactive-oxygen-species generation, which is why mitochondrial, cardiac, and neurodegeneration research models are the dominant demand context. Vialdyne releases lyophilised SS-31 acetate at ≥99.0% HPLC main-peak, with a batch COA available from sales. Depending on the agreed procurement scope, supporting records can cover RP-HPLC purity, peptide-content assay, related substances, water (Karl Fischer), counter-ion, residual solvents, and endotoxin. ESI-MS identity and the raw chromatogram are documented on the same lot for labs assembling a CMC or reference-standard dossier.

Applications & buyer fit

Mitochondrial-targeted peptides ship primarily to research labs studying OXPHOS, ROS biology, and mitochondrial dysfunction in disease models. The lipophilic / cationic character that drives mitochondrial accumulation also makes these peptides somewhat oxidation-prone in solution, working stocks should be prepared fresh or held at -80 °C rather than -20 °C when the workflow permits.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

736992-21-5

Molecular Formula

C32H49N9O5

Molecular Weight

639.80 g/mol

Sequence

D-Arg-Dmt-Lys-Phe-NH2

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

5 mg – 50 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 0.5-1 hour

MOQ

On request

Lead time

10–18 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for SS-31 / Elamipretide; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

SS-31 / Elamipretide

VD260428-2S10190 · 99.04%

VerifiedRequest full COA →

SS-31 / Elamipretide

VD260428-2S50191 · 99.11%

VerifiedRequest full COA →

SS-31 / Elamipretide

VD260428-2S189 · 99.57%

Independent analytical testing

Product- and strength-matched first-page previews are shown separately from Vialdyne's lot-specific Batch COAs. Reference the report number when requesting the complete, high-resolution file from sales.

Third-party testView report record →

SS-31

50 mg · HPLC / MS

SS50-20260806S9397

Regulatory note

Investigational compound; not approved as a finished drug in any jurisdiction. Sold as a research-use-only reference material, not for human or veterinary use.

Selected literature

1. Thompson WR, Hornby B, Manuel R, Bradley E, Laux J, Carr J, Vernon HJ. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet Med. 2021;23(3):471-478.
2. Thompson WR, Manuel R, Abbruscato A, Carr J, Campbell J, Hornby B, Vaz FM, Vernon HJ. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024;26(7):101138.
3. Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023;101(3):e238-e252.
4. Sabbah HN, Gupta RC, Kohli S, et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ Heart Fail. 2017;10(8):e004389.
5. Ehlers JP, Khanani AM, Wykoff CC, et al. ReCLAIM-2: a randomized phase II clinical trial evaluating elamipretide in age-related macular degeneration, geographic atrophy growth, visual function, and ellipsoid zone preservation. Ophthalmol Sci. 2025;5(1):100621.
6. Chavez JD, Tang X, Campbell MD, et al. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci U S A. 2020;117(26):15363-15373.

Frequently asked questions